Journal
CURRENT OPINION IN VIROLOGY
Volume 1, Issue 6, Pages 519-525Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2011.10.008
Keywords
-
Categories
Funding
- NIH [AI057158, AI091707]
- Greenberg Medical Research Institute
- Starr Foundation
- Ronald A. Shellow, M.D. Memorial Fund
- National Research Service Award from the National Institute of Diabetes and Digestive and Kidney Diseases [DK082155]
Ask authors/readers for more resources
Many viruses trigger the type I interferon (IFN) system, leading to the transcription of hundreds of interferon-stimulated genes (ISGs). The products of these ISGs exert numerous antiviral effector functions, many of which are still not fully described. Recent efforts have been aimed at identifying which ISGs are antiviral and further characterizing their mechanisms of action. IFN effectors vary widely in their magnitude of inhibitory activity and display combinatorial antiviral properties. Collectively, ISGs can target almost any step in a virus life cycle. Some of the most potent antiviral effectors reinforce the system by further inducing IFN or ISGs. Other genes enhance or facilitate viral replication, suggesting that some viruses may have evolved to co-opt IFN effectors for a survival advantage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available